FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)
Access, dose optimization and real-world data for Lu-177
FDA expands Pluvicto approval; industry reaction
PSMAddition trial: earlier Lu-177 delays metastatic progression
Related Stories
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 15 days
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 5 wks
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 2 months
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 2 months
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 2 months
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 2 months
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supplements, Pediatric Oncology, CDC, Rural Health and look for the RSS link.
StackHealth Time Machine